<p>Lake Street Capital 的研究分析师在周五向投资者发布的研究报告中开始覆盖 OncoCyte（NASDAQ:OCX - 获取免费报告）股票。该公司给予该股票 &#34;买入&#34; 评级，并设定了 5.00 美元的目标价。Lake Street Capital 的目标价表明，相较于公司之前的收盘价，潜在上涨幅度为 55.28%。</p>
<p>其他几位股票研究分析师也最近对 OCX 发表了看法。Stephens 在周二重申了 &#34;持平&#34; 评级，并对 OncoCyte 的股票设定了 4.00 美元的目标价。Needham &amp; Company LLC 在周二重申了 &#34;买入&#34; 评级，并设定了 4.25 美元的目标价。最后，StockNews.com 在 1 月 13 日的报告中开始覆盖 OncoCyte 股票，并给予该公司 &#34;卖出&#34; 评级。一位分析师对该股票给予了卖出评级，一位给予了持有评级，三位给予了买入评级。根据 MarketBeat 的数据，OncoCyte 目前的平均评级为 &#34;持有&#34;，共识目标价为 4.56 美元。</p>
<p><strong>阅读我们最新的 OCX 研究报告</strong></p>
<h2>OncoCyte 股票上涨 1.3%</h2>
<p>OncoCyte 股票周五开盘价为 3.22 美元。OncoCyte 的 52 周低点为 1.92 美元，52 周高点为 4.75 美元。该公司的 50 日移动平均价格为 2.77 美元，200 日移动平均价格为 2.73 美元。公司的市值为 5620 万美元，市盈率为 -0.73，贝塔值为 0.79。</p>
<p>OncoCyte（NASDAQ:OCX - 获取免费报告）最近于 3 月 24 日发布了季度财报。公司报告每股收益（EPS）为 0.48 美元，超出市场共识预期的 -0.40 美元，超出幅度为 0.88 美元。OncoCyte 的净利润率为 -6122.29%，股本回报率为 -269.32%。该季度的营业收入为 149 万美元，而分析师预期为 16 万美元。整体来看，股票研究分析师预测 OncoCyte 本财年的每股收益将为 -2.57 美元。</p>
<h2>内部人士买卖</h2>
<p>在相关消息中，首席财务官 Andrea S. James 于 2 月 7 日星期五购买了 97,561 股公司的股票。该股票的平均购买成本为每股 2.05 美元，总价值为 200,000.05 美元。收购完成后，首席财务官现在持有 151,231 股公司的股票，价值 310,023.55 美元。此次交易使其持股增加了 181.78%。该交易已在向 SEC 提交的文件中披露，相关信息可通过 SEC 网站获取。此外，主要股东 Patrick W. Smith 于 2 月 7 日星期五购买了 1,077,600 股公司的股票。该股票的平均购买成本为每股 2.05 美元，总交易额为 2,209,080.00 美元。购买后，该内部人士现在直接持有 2,872,671 股公司股票，价值约 5,888,975.55 美元。这笔交易使其持股增加了 60.03%。该购买的披露信息可在此处找到。过去 90 天内，内部人士共购买了价值 2,430,510 美元的 1,185,625 股公司股票。内部人士持有公司股票的比例为 1.58%。</p>
<h2>机构投资者对 OncoCyte 的看法</h2>
<p>几家对冲基金最近调整了对公司的持股。Geode Capital Management LLC 在第三季度将其在 OncoCyte 的持股增加了 12.2%。Geode Capital Management LLC 目前持有 103,980 股公司股票，价值 296,000 美元，此前在上个季度购买了额外的 11,289 股。FNY Investment Advisers LLC 在第四季度将其在 OncoCyte 的持股增加了 15.1%。FNY Investment Advisers LLC 目前持有 49,377 股公司股票，价值 117,000 美元，此前在此期间购买了额外的 6,481 股。Pura Vida Investments LLC 在第四季度将其在 OncoCyte 的持股增加了 32.1%。Pura Vida Investments LLC 目前持有 654,451 股公司股票，价值 1,558,000 美元，此前在上个季度购买了额外的 159,106 股。Two Sigma Securities LLC 在第四季度获得了 OncoCyte 的新股份，价值 31,000 美元。最后，Broadwood Capital Inc. 在第四季度将其在 OncoCyte 的持股增加了 26.7%。Broadwood Capital Inc. 目前持有 6,244,405 股公司股票，价值 14,862,000 美元，此前在上个季度购买了额外的 1,315,339 股。55.35% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 OncoCyte</h2>
<p>（获取免费报告）</p>
<p>OncoCyte Corporation 是一家精准诊断公司，专注于在美国和国际上开发和商业化专有检测。该公司正在开发 DetermaIO，一种基因表达检测，用于评估肿瘤微环境以预测对免疫疗法的反应；DetermaCNI，一种用于监测癌症患者治疗效果的血液监测工具；以及 VitaGraft，一种用于监测血液基础的实质性器官移植的检测。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 OncoCyte</li>
<li>三只可以提升您投资组合的家居改善股票</li>
<li>购买 Chewy 股票反转？这是现在的理由</li>
<li>股票拆分意味着什么？</li>
<li>Ibotta 股票：为什么回购看起来像是一个看涨的赌注</li>
<li>百分比收益者告诉投资者什么，以及为什么它们没有告诉全部故事</li>
<li>Joby Aviation 股票：分析师信心与聪明资金一致</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元于 OncoCyte 吗？</h2>
<p>在您考虑 OncoCyte 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 OncoCyte 并不在名单上。</p>
<p>虽然 OncoCyte 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IMDX

<p>Lake Street Capital 已经开始对 OncoCyte (NASDAQ:OCX) 进行覆盖，给予 “买入” 评级，目标价为 5.00 美元，意味着潜在上涨幅度为 55.28%。其他分析师的评级则各有不同，平均共识为 “持有”，目标价为 4.56 美元。OncoCyte 的股票开盘价为 3.22 美元，52 周范围为 1.92 美元至 4.75 美元。该公司报告每股收益为 0.48 美元，超出预期。内部人士购买活动增加，首席财务官 Andrea S. James 和主要股东 Patrick W. Smith 进行了大量购买</p>

<p>Research analysts at Lake Street Capital initiated coverage on shares of OncoCyte (NASDAQ:OCX - Get Free Report) in a research note issued to investors on Friday,Briefing.com Automated Import reports. The firm set a &#34;buy&#34; rating and a $5.00 price target on the stock. Lake Street Capital's price target indicates a potential upside of 55.28% from the company's previous close.</p>
<div class="lb-trans"><p>Lake Street Capital 的研究分析师在周五向投资者发布的研究报告中开始覆盖 OncoCyte（NASDAQ:OCX - 获取免费报告）股票。该公司给予该股票 &#34;买入&#34; 评级，并设定了 5.00 美元的目标价。Lake Street Capital 的目标价表明，相较于公司之前的收盘价，潜在上涨幅度为 55.28%。</p>
</div><p>Several other equities research analysts also recently weighed in on OCX. Stephens reissued an &#34;equal weight&#34; rating and issued a $4.00 price target on shares of OncoCyte in a report on Tuesday. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $4.25 target price on shares of OncoCyte in a research report on Tuesday. Finally, StockNews.com assumed coverage on shares of OncoCyte in a report on Monday, January 13th. They issued a &#34;sell&#34; rating for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, OncoCyte presently has an average rating of &#34;Hold&#34; and a consensus price target of $4.56.</p>
<div class="lb-trans"><p>其他几位股票研究分析师也最近对 OCX 发表了看法。Stephens 在周二重申了 &#34;持平&#34; 评级，并对 OncoCyte 的股票设定了 4.00 美元的目标价。Needham &amp; Company LLC 在周二重申了 &#34;买入&#34; 评级，并设定了 4.25 美元的目标价。最后，StockNews.com 在 1 月 13 日的报告中开始覆盖 OncoCyte 股票，并给予该公司 &#34;卖出&#34; 评级。一位分析师对该股票给予了卖出评级，一位给予了持有评级，三位给予了买入评级。根据 MarketBeat 的数据，OncoCyte 目前的平均评级为 &#34;持有&#34;，共识目标价为 4.56 美元。</p>
</div><p><strong>Read Our Latest Research Report on OCX</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 OCX 研究报告</strong></p>
</div><h2>OncoCyte Stock Up 1.3 %</h2>
<div class="lb-trans"><h2>OncoCyte 股票上涨 1.3%</h2>
</div><p>Shares of OncoCyte stock opened at $3.22 on Friday. OncoCyte has a 52-week low of $1.92 and a 52-week high of $4.75. The firm's 50 day moving average price is $2.77 and its 200-day moving average price is $2.73. The company has a market cap of $56.20 million, a P/E ratio of -0.73 and a beta of 0.79.</p>
<div class="lb-trans"><p>OncoCyte 股票周五开盘价为 3.22 美元。OncoCyte 的 52 周低点为 1.92 美元，52 周高点为 4.75 美元。该公司的 50 日移动平均价格为 2.77 美元，200 日移动平均价格为 2.73 美元。公司的市值为 5620 万美元，市盈率为 -0.73，贝塔值为 0.79。</p>
</div><p>OncoCyte (NASDAQ:OCX - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.88. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. The business had revenue of $1.49 million for the quarter, compared to analyst estimates of $0.16 million. As a group, equities research analysts forecast that OncoCyte will post -2.57 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>OncoCyte（NASDAQ:OCX - 获取免费报告）最近于 3 月 24 日发布了季度财报。公司报告每股收益（EPS）为 0.48 美元，超出市场共识预期的 -0.40 美元，超出幅度为 0.88 美元。OncoCyte 的净利润率为 -6122.29%，股本回报率为 -269.32%。该季度的营业收入为 149 万美元，而分析师预期为 16 万美元。整体来看，股票研究分析师预测 OncoCyte 本财年的每股收益将为 -2.57 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In related news, CFO Andrea S. James purchased 97,561 shares of the firm's stock in a transaction on Friday, February 7th. The stock was bought at an average cost of $2.05 per share, with a total value of $200,000.05. Following the completion of the acquisition, the chief financial officer now owns 151,231 shares of the company's stock, valued at $310,023.55. The trade was a 181.78 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Patrick W. Smith acquired 1,077,600 shares of the company's stock in a transaction dated Friday, February 7th. The shares were purchased at an average cost of $2.05 per share, for a total transaction of $2,209,080.00. Following the purchase, the insider now directly owns 2,872,671 shares in the company, valued at approximately $5,888,975.55. This trade represents a 60.03 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 1,185,625 shares of company stock valued at $2,430,510 over the last 90 days. Insiders own 1.58% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Andrea S. James 于 2 月 7 日星期五购买了 97,561 股公司的股票。该股票的平均购买成本为每股 2.05 美元，总价值为 200,000.05 美元。收购完成后，首席财务官现在持有 151,231 股公司的股票，价值 310,023.55 美元。此次交易使其持股增加了 181.78%。该交易已在向 SEC 提交的文件中披露，相关信息可通过 SEC 网站获取。此外，主要股东 Patrick W. Smith 于 2 月 7 日星期五购买了 1,077,600 股公司的股票。该股票的平均购买成本为每股 2.05 美元，总交易额为 2,209,080.00 美元。购买后，该内部人士现在直接持有 2,872,671 股公司股票，价值约 5,888,975.55 美元。这笔交易使其持股增加了 60.03%。该购买的披露信息可在此处找到。过去 90 天内，内部人士共购买了价值 2,430,510 美元的 1,185,625 股公司股票。内部人士持有公司股票的比例为 1.58%。</p>
</div><h2>Institutional Investors Weigh In On OncoCyte</h2>
<div class="lb-trans"><h2>机构投资者对 OncoCyte 的看法</h2>
</div><p>Several hedge funds have recently modified their holdings of the company. Geode Capital Management LLC increased its stake in shares of OncoCyte by 12.2% in the 3rd quarter. Geode Capital Management LLC now owns 103,980 shares of the company's stock valued at $296,000 after purchasing an additional 11,289 shares in the last quarter. FNY Investment Advisers LLC raised its stake in shares of OncoCyte by 15.1% during the 4th quarter. FNY Investment Advisers LLC now owns 49,377 shares of the company's stock worth $117,000 after buying an additional 6,481 shares during the period. Pura Vida Investments LLC lifted its position in shares of OncoCyte by 32.1% during the 4th quarter. Pura Vida Investments LLC now owns 654,451 shares of the company's stock valued at $1,558,000 after buying an additional 159,106 shares in the last quarter. Two Sigma Securities LLC acquired a new stake in OncoCyte in the 4th quarter valued at $31,000. Finally, Broadwood Capital Inc. increased its holdings in OncoCyte by 26.7% in the 4th quarter. Broadwood Capital Inc. now owns 6,244,405 shares of the company's stock worth $14,862,000 after acquiring an additional 1,315,339 shares in the last quarter. 55.35% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对公司的持股。Geode Capital Management LLC 在第三季度将其在 OncoCyte 的持股增加了 12.2%。Geode Capital Management LLC 目前持有 103,980 股公司股票，价值 296,000 美元，此前在上个季度购买了额外的 11,289 股。FNY Investment Advisers LLC 在第四季度将其在 OncoCyte 的持股增加了 15.1%。FNY Investment Advisers LLC 目前持有 49,377 股公司股票，价值 117,000 美元，此前在此期间购买了额外的 6,481 股。Pura Vida Investments LLC 在第四季度将其在 OncoCyte 的持股增加了 32.1%。Pura Vida Investments LLC 目前持有 654,451 股公司股票，价值 1,558,000 美元，此前在上个季度购买了额外的 159,106 股。Two Sigma Securities LLC 在第四季度获得了 OncoCyte 的新股份，价值 31,000 美元。最后，Broadwood Capital Inc. 在第四季度将其在 OncoCyte 的持股增加了 26.7%。Broadwood Capital Inc. 目前持有 6,244,405 股公司股票，价值 14,862,000 美元，此前在上个季度购买了额外的 1,315,339 股。55.35% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About OncoCyte</h2>
<div class="lb-trans"><h2>关于 OncoCyte</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.</p>
<div class="lb-trans"><p>OncoCyte Corporation 是一家精准诊断公司，专注于在美国和国际上开发和商业化专有检测。该公司正在开发 DetermaIO，一种基因表达检测，用于评估肿瘤微环境以预测对免疫疗法的反应；DetermaCNI，一种用于监测癌症患者治疗效果的血液监测工具；以及 VitaGraft，一种用于监测血液基础的实质性器官移植的检测。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than OncoCyte</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Buy the Chewy Stock Reversal? Here’s Why Now Is the Time</li>
<li>What Does a Stock Split Mean?</li>
<li>Ibotta Stock: Why the Buyback Looks Like a Bullish Bet</li>
<li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li>
<li>Joby Aviation Stock: Analyst Confidence and Smart Money Align</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 OncoCyte</li>
<li>三只可以提升您投资组合的家居改善股票</li>
<li>购买 Chewy 股票反转？这是现在的理由</li>
<li>股票拆分意味着什么？</li>
<li>Ibotta 股票：为什么回购看起来像是一个看涨的赌注</li>
<li>百分比收益者告诉投资者什么，以及为什么它们没有告诉全部故事</li>
<li>Joby Aviation 股票：分析师信心与聪明资金一致</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in OncoCyte Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元于 OncoCyte 吗？</h2>
</div><p>Before you consider OncoCyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 OncoCyte 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OncoCyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 OncoCyte 并不在名单上。</p>
</div><p>While OncoCyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 OncoCyte 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Lake Street Capital 的分析师开始对 OncoCyte（NASDAQ:OCX）进行覆盖